ArticleOpen forum infectious diseases2020
Persistent Systemic Microbial Translocation, Inflammation, and Intestinal Damage During
Article in Open forum infectious diseases, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 1 synthesis or guideline pooled it, 26 citations in OpenAlex.
- Do patients receiving extracorporeal membrane-oxygenation need antibiotic prophylaxis? A systematic review and meta-analysis on 7,996 patients.BMC anesthesiology · 2024Pooled it
- Enteric Infections, Dysbiosis, and Metabolic Dysfunction: The Role of Diarrheagenic Pathogens in Insulin Resistance.International journal of molecular sciences · 2026Review
- Central Line-Related Bloodstream Infection byMicroorganisms · 2025Article
- Special Issue: "Molecular Research in Human Microbiome 2.0".International journal of molecular sciences · 2025Article
- Serum markers of microbial translocation and intestinal damage in assessment of gastrointestinal tract involvement in systemic sclerosis.Clinical and experimental medicine · 2024Article
- Article
- Molecular Research in Human Microbiome.International journal of molecular sciences · 2023Article
- Risk factors for carbapenem-resistantJAC-antimicrobial resistance · 2023Article
- Increased Incidence and Risk of Septicemia and Urinary Tract Infection AfterOpen forum infectious diseases · 2023Article
- Atherosclerotic Cardiovascular Disease in Inflammatory Bowel Disease: The Role of Chronic Inflammation and Platelet Aggregation.Medicina (Kaunas, Lithuania) · 2023Article
- Article
- The microbiota as a modulator of mucosal inflammation and HIV/HPV pathogenesis: From association to causation.Frontiers in immunology · 2023Review
- Morphological Assessment and Biomarkers of Low-Grade, Chronic Intestinal Inflammation in Production Animals.Animals : an open access journal from MDPI · 2022Review
- Mucosal Immunity and the Gut-Microbiota-Brain-Axis in Neuroimmune Disease.International journal of molecular sciences · 2022Review
- Clinical Impact of COVID-19 on Multi-Drug-Resistant Gram-Negative Bacilli Bloodstream Infections in an Intensive Care Unit Setting: Two Pandemics Compared.Antibiotics (Basel, Switzerland) · 2022Article
- Concurrent and Subsequent Co-Infections ofMicroorganisms · 2022Review
- Article
- Article
- Proinflammatory Cytokines: Possible Accomplices for the Systemic Effects ofJournal of inflammation research · 2021Article
- Persistent Systemic Microbial Translocation and Intestinal Damage During Coronavirus Disease-19.Frontiers in immunologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
background
methodsPatients with documented CDI were enrolled in the study. For each subject, plasma samples were collected at T0 and T1 (before and after CDI therapy, respectively), and the following markers were evaluated: lipopolysaccharide-binding protein (LPB), EndoCab IgM, interleukin-6, intestinal fatty acid binding protein (I-FABP). Samples from nonhospitalized healthy controls were also included. The study population was divided into BSI+/BSI- and fecal microbiota transplantation (FMT) +/FMT- groups, according to the development of n-BSI and the receipt of FMT, respectively.
resultsOverall, 45 subjects were included; 8 (17.7%) developed primary n-BSI. Markers of microbial translocation and intestinal damage significantly decreased between T0 and T1, however, without reaching values similar to controls (
conclusionsCDI is associated with high levels of microbial translocation, inflammation, and intestinal damage, which are still present at clinical resolution of CDI. The role of residual mucosal perturbation and persistence of intestinal cell damage in the development of n-BSI following CDI, as well as the possible effect of FMT in the restoration of mucosal integrity, should be further investigated.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.